Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACVRL1 | P37023 | 8/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14313307 | 0.93 | ACVRL1 (0.43) | ACVRL1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL14313411 | 0.92 | ACVRL1 (0.39) | ACVRL1TNK2PDE2A | |
| SCHEMBL14313914 | 0.91 | ACVRL1 (0.41) | ACVRL1TNK2ALDH1A1PDE2A | |
| SCHEMBL14898496 | 0.90 | ACVRL1 (0.48) | KMT2AACVRL1TNK2ALDH1A1 | |
| SCHEMBL14312877 | 0.90 | ACVRL1 (0.48) | KMT2AACVRL1TNK2ALDH1A1 | |
| SCHEMBL14312731 | 0.89 | ACVRL1 (0.46) | ACVRL1TNK2 | |
| SCHEMBL14327133 | 0.88 | ACVRL1 (0.40) | KMT2AACVRL1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL14312573 | 0.87 | ACVRL1 (0.41) | KMT2AACVRL1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL14313237 | 0.87 | ACVRL1 (0.46) | ACVRL1TNK2 | |
| SCHEMBL14312638 | 0.87 | ACVRL1 (0.43) | ACVRL1TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945222-B1 | PYRROLO[2,1-F] [1,2,4]-TRIAZIN-4-YLAMINES AS IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | Bayer Pharma AG (DE) | 2012-12-26 | — | — | EP | disclosed |